Allergan

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland.

AbbVie

Shares of drug makers were getting a nice boost in premarket trading Tuesday, after AbbVie Inc. deal to buy Allergan for a 45% premium.

Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium

AbbVie is paying a 45% premium over the Botox manufacturer's closing price on Monday.

AbbVie to Buy Allergan in a $63 Billion Deal

Drugmaker AbbVie Inc (NYSE: ABBV) has reached a deal to acquire Allergan (NYSE: AGN) for $63 billion.

AbbVie To Acquire Allergan In $63B Deal

AbbVie Inc. ABBV, -0.42% confirmed Tuesday a deal to buy pharmaceutical company Allergan PLC AGN, -0.95% in a deal with valued at $63 billion.

AbbVie confirms deal to buy Allergan for 45% premium, valuing Allergan at $61.7 billion

AbbVie Inc said on Tuesday it would acquire Botox-maker Allergan Plc  in a cash-and-stock deal for about $63 billion.

AbbVie to buy Allergan in $63 billion deal

AbbVie said it would buy Botox-maker Allergan for about $63 billion.

AbbVie agrees to buy Allergan for about $63 billion in a cash and stock deal

Shares of Allergan PLC AGN, -0.95% soared 35% toward an 8-month high in premarket trading Tuesday, after The Wall Street Journal reported that AbbVie Inc.

Allergan's stock soars after WSJ report AbbVie near a buyout deal for a 45% premium

The U.S. Food and Drug Administration has approved Allergan Plc's AGN, -1.14% CoolTone device for use in strengthening, toning and firming the abdominal area, buttocks and thighs, Allergan said Monday.

FDA approves Allergan's CoolTone device for toning up abdomen, buttocks and thighs

Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.

Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids

Allergan PLC AGN, +2.08% said Friday that its supplemental biologics application (sBLA) for Botox for the treatment of upper limb spasticity in pediatric patients, from ages 2 to 17, was approved by the U.S.

Allergan's sBLA for Botox for pediatric patients approved by FDA

Allergan (AGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Allergan (AGN) in Focus: Stock Moves 6.2% Higher

Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.

Allergan Up As Analyst Statement Sparks Business Split Rumors

Abeona Therapeutics

Alexion Pharma

Amgen

Regeneron Pharmaceuticals

Savara

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data

Shares of the small-cap, actively traded Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) were seeing positive momentum Wednesday on top of the 8.08% gain the stock recorded Tuesday.

Ironwood, Allergan Investors React Positively After Duo's Constipation Drug Found Effective

Broadcom

Boeing

Etsy

Allergan looks to still be in a downtrend, while Etsy stock is fighting with resistance at $70 and Boeing hurdles the 50-day moving average.

5 Top Stock Trades for Wednesday

Shares of Allergan Plc AGN, +4.42% shot up 3.8% Tuesday afternoon after Evercore ISI analyst Umer Raffat said a call with the drugmaker's general counsel left him "with the sense that Allergan is heading towards a split and may likely lay out timelines.

Allergan stock jumps 3.8% after Evercore ISI analyst says company is likely heading toward a split

CenturyLink

Charles Schwab

The stock charts of Centurylink, Allergan and Charles Schwab are prepared to get the new trading week started with a bang.

3 Big Stock Charts for Monday: Centurylink, Allergan and Charles Schwab

Mizuho Financial Group

Occidental Petroleum

Vodafone Group

Vodafone Group PLC (VOD), Allergan PLC (AGN), Occidental Petroleum Corp. (OXY), and Mizuho Financial Group Inc. (MFG) have declined to their respective three-year lows.

Stocks That Fell to 3-Year Lows in the Week of June 14

FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.

Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti

BJ`s Wholesale Club Holdings Inc

Domino's Pizza

Transocean

Marriott Vacations Worldwide

WPX Energy

As stocks pullback from record highs, lowered market valuations are making a number of companies look like strong potential takeover targets.

7 Stocks Ripe for M&A as Trade War Pushes Market Off Record Highs

Allergan (AGN) reported earnings 30 days ago. What's next for the stock?

Allergan (AGN) Down 9.7% Since Last Earnings Report: Can It Rebound?

Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.

Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression

Shares of Allergan headed lower and now trade at below 8 times forward earnings.

Buy Allergan After Recent Dip

CRISPR Therapeutics

Vertex Pharmaceuticals

XBiotech

Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?

5 Growthy Biotech Stocks to Buy Despite the Scrutiny

Here's why the drugmaker topped revenue and earnings expectations in Q1.

News for Allergan Stock (AGN)